Zobrazeno 1 - 10
of 87
pro vyhledávání: ''
Autor:
Elise Klæstad, Signe Opdahl, Monica J. Engstrøm, Elisabeth Wik, Borgny Ytterhus, Anna M. Bofin, Marit Valla
Publikováno v:
Breast Cancer Research and Treatment
Purpose MRPS23 is recognized as a driver of proliferation in luminal breast cancer. The aims of the present study were to describe MRPS23 copy number change in breast cancer, and to assess associations between MRPS23 copy number change and molecular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49102c4df90ac263d4c308ee2094e138
https://hdl.handle.net/11250/2672584
https://hdl.handle.net/11250/2672584
Autor:
Liisa M. Pelttari, Paula Poikonen-Saksela, Kristiina Aittomäki, Päivi Auvinen, Arja Jukkola-Vuorinen, Sanna Hallamies, Heli Nevanlinna, Johanna Mattson, Carl Blomqvist, Antti Jekunen
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-5 (2017)
BMC Cancer
BMC Cancer
Background Several susceptibility genes have been established for female breast cancer, of which mutations in BRCA1 and especially in BRCA2 are also known risk factors for male breast cancer (MBC). The role of other breast cancer genes in MBC is less
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4819e7805611ab5361165ecad3b1625
https://erepo.uef.fi/handle/123456789/5171
https://erepo.uef.fi/handle/123456789/5171
Publikováno v:
Cancer Immunology, Immunotherapy
To examine the relationship between cytotoxic T lymphocyte antigen 4 (CTLA-4) expression and breast cancer prognosis, CTLA-4 expression was immunohistochemically detected in paraffin-embedded specimens of primary tumors from 130 patients with breast
Autor:
Tianfeng Wang, Ai-ping Lu, Yiqiang Liu, Yijun Zhou, Zhaoqing Fan, Tao Ouyang, Yuntao Xie, Jinfeng Li, Yingjian He
Publikováno v:
Breast Cancer Research and Treatment
This study aimed to compare the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer. Five-hundred and one patients with clinical stage I-III invasive breast cancer were randomly assig
Autor:
M E, Cazzaniga, L, Cortesi, A, Ferzi, L, Scaltriti, F, Cicchiello, M, Ciccarese, S, Della Torre, F, Villa, M, Giordano, C, Verusio, M, Nicolini, A R, Gambaro, L, Zanlorenzi, E, Biraghi, L, Legramandi, E, Rulli, Valter, Torri
Publikováno v:
Breast Cancer Research and Treatment
Purpose: The VICTOR-1 study demonstrated that the all-oral metronomic combination of vinorelbine and capecitabine is highly active and well tolerated in hormone receptor-positive/HER2-negative patients. The VICTOR-2 study was designed to confirm thes
Autor:
G. Kunz, Peter A. Fasching, Steve Chan, P. Krivorotko, M. Higgins, A. Ferro, F. F. Lehmann, Sherko Kuemmel, Giuseppe Curigliano, P. M. De Sousa Alves, Lee S. Schwartzberg, Mario Campone, Thomas Bachelot, Marc Gillet, Paul E. Goss, V. Wascotte, Véronique Diéras
Publikováno v:
Breast Cancer Research and Treatment
Purpose This Phase I, multicenter, randomized study (ClinicalTrials.gov NCT01220128) evaluated the safety and immunogenicity of recombinant Wilms’ tumor 1 (WT1) protein combined with the immunostimulant AS15 (WT1-immunotherapeutic) as neoadjuvant t
Autor:
Antonio C. Wolff, Allison M. Deal, Amal Melhem-Bertrandt, Nan Lin, Lisa A. Carey, Olga Karginova, Carey K. Anders, J. Keith Smith, Charles M. Perou, Eric P. Winer, John T. Carpenter, Vandana G. Abramson, P. Kelly Marcom, Rita Nanda, Joel S. Parker, Vered Stearns, Amy H. Peterman, Aleix Prat, Anna Maria Storniolo, Michelle E. Melisko, Catherine Van Poznak, Minetta C. Liu, Shannon Puhalla, Jonathan S. Berg
Publikováno v:
Breast Cancer Research and Treatment
Nearly half of patients with advanced triple negative breast cancer (TNBC) develop brain metastases (BM) and most will also have uncontrolled extracranial disease. This study evaluated the safety and efficacy of iniparib, a small molecule anti-cancer
Autor:
Pawel Jozwiak, Anna Krzeslak, Hanna Romanowicz, Katarzyna Wójcik-Krowiranda, Ewa Forma, Andrzej Bieńkiewicz, Magdalena Brys
Publikováno v:
Pathology Oncology Research
Cancer cells have accelerated metabolism and high glucose requirements. The up-regulation of specific glucose transporters may represent a key mechanism by which malignant cells may achieve increased glucose uptake to support the high rate of glycoly
Autor:
Erhan Berrak, Linda T. Vahdat, David Cox, Stefan Glück, Joyce O'Shaughnessy, Kristi McIntyre, James Song, Lee S. Schwartzberg
Publikováno v:
Breast Cancer Research and Treatment
Eribulin mesylate, a novel non-taxane microtubule dynamics inhibitor, is approved for treatment of metastatic breast cancer (MBC) in patients who have previously received at least 2 chemotherapeutic regimens for MBC that should have included an anthr
Autor:
William E. Barlow, Stanley Vogel, Kristine Rinn, Kim Z Dammann, Danika Lew, Gabriel N. Hortobagyi, Julie R. Gralow, Robert B. Livingston, George Somlo, Lucas Wong
Publikováno v:
Breast Cancer Research and Treatment
Docetaxel and vinorelbine have demonstrated Single-agent activity in breast cancer. Preclinical studies suggest potential synergy between these antitubulin chemotherapy agents. This study evaluates these drugs in combination in metastatic breast canc